Terms: = Ovarian cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Staging
12 results:
1. Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
Mert I; Kumar A; Torres D; Huang Y; McGree ME; Weaver AL; Cliby WA
Gynecol Oncol; 2019 May; 153(2):238-241. PubMed ID: 30833135
[TBL] [Abstract] [Full Text] [Related]
2. Novel Surgical Strategies in the Treatment of Gynecological Malignancies.
Angeles MA; Martínez-Gómez C; Migliorelli F; Voglimacci M; Figurelli J; Motton S; Tanguy Le Gac Y; Ferron G; Martinez A
Curr Treat Options Oncol; 2018 Nov; 19(12):73. PubMed ID: 30411170
[TBL] [Abstract] [Full Text] [Related]
3. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract] [Full Text] [Related]
4. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
Almadrones L
Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
[TBL] [Abstract] [Full Text] [Related]
5. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
[TBL] [Abstract] [Full Text] [Related]
6. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study.
Moore DH; Valea F; Walton LA; Soper J; Clarke-Pearson D; Fowler WC
Gynecol Oncol; 1995 Nov; 59(2):267-72. PubMed ID: 7590485
[TBL] [Abstract] [Full Text] [Related]
7. Chromic phosphate therapy in carcinoma of the ovary.
Goodman A; Bornstein L; Ball H; Smith DM; Bankoff M
J Am Coll Surg; 1994 Oct; 179(4):401-6. PubMed ID: 7921388
[TBL] [Abstract] [Full Text] [Related]
8. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract] [Full Text] [Related]
9. Chemotherapy in ovarian carcinoma: present role and future prospects.
Thigpen JT; Blessing JA; Vance RB; Lambuth BW
Semin Oncol; 1989 Aug; 16(4 Suppl 6):58-65. PubMed ID: 2669138
[TBL] [Abstract] [Full Text] [Related]
10. ovarian carcinoma: the role of chemotherapy.
Thigpen JT; Vance RB; Lambuth BW
Semin Oncol; 1988 Jun; 15(3 Suppl 3):16-23. PubMed ID: 3293214
[TBL] [Abstract] [Full Text] [Related]
11. Complications of Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma.
de Graaf PW; Mellema MM; ten Bokkel Huinink WW; Aartsen EJ; Dubbelman R; Franklin HR; Hart AA
Gynecol Oncol; 1988 Jan; 29(1):43-9. PubMed ID: 3338663
[TBL] [Abstract] [Full Text] [Related]
12. [Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC)].
Takizawa K; Ino Y; Isono T; Sato M; Iguchi T; Takeda Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1877-83. PubMed ID: 3109329
[TBL] [Abstract] [Full Text] [Related]
